Skip to main content
SpringerLink
Log in

Review of Lifestyle and CAM for Miscellaneous Urologic Topics (Bladder Cancer, CP/CPPS, IC/PBS, Kidney Cancer): Part One

  • Chapter
  • First Online:
Book cover Complementary & Alternative Medicine for Prostate and Urologic Health

Abstract

Multiple lifestyle changes have the ability to prevent bladder cancer (smoking cessation, reduce arsenic concentrations in water, increase cruciferous vegetable intake, etc.), and some dietary supplements, such as Lactobacillus casei Shirota, have the ability to reduce recurrence rates after superficial bladder cancer treatment from three randomized clinical trials. Chewing gum could be an option for patients post-cystectomy to improve bowel recovery time. Exercise could be a treatment option for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), and a variety of dietary supplements (quercetin complex, cernilton, etc.) are currently being utilized as part of the greater UPOINT conventional treatment paradigm. Interstitial cystitis/painful bladder syndrome (IC/PBS) has also being utilized CAM with some good efficacy and compliance. For example, elimination and restriction diets based on triggers as well as calcium glycerophosphate, glucosamine, chondroitin, hyaluronate, and quercetin complex may help patients with IC/PBS. And kidney cancer, compared to almost any other cancer, has some of the strongest associations with cardiovascular risk factors, especially obesity, smoking and hypertension, and a reduction in risk with exercise and dietary changes. Multiple urologic disease risks and even outcomes could be positively or negatively affected by CAM and should be objectively discussed with patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Grossman HB, Stenzl A, Moyad MA, Droller MJ. Bladder cancer: chemoprevention, complementary approaches and budgetary considerations. Scand J Urol Nephrol Suppl. 2008;218:213–33.

    Article  PubMed  Google Scholar 

  2. Vilensky D, Lawrentschuk N, Hersey K, Fleshner NE. A smoking cessation program as a resource for bladder cancer patients. Can Urol Assoc J. 2012;6(5): E167–73.

    Article  PubMed  Google Scholar 

  3. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306:737–45.

    Article  PubMed  CAS  Google Scholar 

  4. Rink M, Xylinas E, Babjuk M, Hansen J, Pycha A, Comploj E, et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol. 2012;188:2120–7.

    Article  PubMed  Google Scholar 

  5. Letasiova S, Medveova A, Sovcikova A, Dusinska M, Volkovova K, Mosolu C, et al. Bladder cancer, a review of environmental risk factors. Environ Health. 2012;11 Suppl 1:11.

    Article  Google Scholar 

  6. Flore MC, Baker TB. Should clinicians encourage smoking cessation for every patient who smokes? JAMA. 2013;309:1032–3.

    Article  Google Scholar 

  7. Stewart SB, Freedland SJ. Influence of obesity on the incidence and treatment of genitourinary malignancies. Urol Oncol. 2011;29:476–86.

    Article  PubMed  Google Scholar 

  8. Chromecki TF, Cha EK, Fajkovic H, Rink M, Ehdaie B, Svatek RS, et al. Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. BJU Int. 2013;111:249–55.

    Article  PubMed  Google Scholar 

  9. Liu B, Mao Q, Lin Y, Zhou F, Xie L. The association of cruciferous vegetables intake and risk of bladder cancer: a meta-analysis. World J Urol. 2013;31:127–33.

    Article  PubMed  CAS  Google Scholar 

  10. Michaud DS, Spiegelman D, Clinton SK, Rimm EB, Willett WC, Glovannucci EL. Fruit and vegetable intake and incidence of bladder cancer in a male prospective cohort. J Natl Cancer Inst. 1999;91:605–13.

    Article  PubMed  CAS  Google Scholar 

  11. Lee JE, Mannisto S, Spiegelman D, Hunter DJ, Bernstein L, van den Brandt PA, et al. Intake of fruits, vegetables, and carotenoids and renal cell cancer risk: a pooled analysis of 13 prospective studies. Cancer Epidemiol Biomarkers Prev. 2009;18:1730–9.

    Article  PubMed  CAS  Google Scholar 

  12. Zhou J, Smith S, Giovannucci E, Michaud DS. Reexamination of total fluid intake and bladder cancer in the Health Professionals Follow-up Study Cohort. Am J Epidemiol. 2012;175:696–705.

    Article  PubMed  Google Scholar 

  13. Donat SM, Bayuga S, Herr HW, Berwick M. Fluid intake and the risk of tumor recurrence in patients with superficial bladder cancer. J Urol. 2003;170: 1777–80.

    Article  PubMed  Google Scholar 

  14. Curhan GC, Willett WC, Rimm EB, Spiegelman D, Stampfer MJ. Prospective study of beverage use and the risk of kidney stones. Am J Epidemiol. 1996;143:240–7.

    Article  PubMed  CAS  Google Scholar 

  15. Ferris J, Berbel O, Alonso-Lopez J, Garcia J, Ortega JA. Environmental non-occupational risk factors associated with bladder cancer. Actas Urol Esp. 2013 [Epub ahead of print].

    Google Scholar 

  16. Brinkman MT, Karagas MR, Zens MS, Schned AR, Reulen RC, Zeegers MP. Intake of alpha-linolenic acid and other fatty acids in relation to the risk of bladder cancer: results from the New Hampshire case–control study. Br J Nutr. 2011;106:1070–7.

    Article  PubMed  CAS  Google Scholar 

  17. Zhang XL, Geng J, Zhang XP, Peng B, Che JP, Yan Y, et al. Statin use and risk of bladder cancer: a meta-analysis. Cancer Causes Control. 2013;24:769–76.

    Article  PubMed  Google Scholar 

  18. Silva RD, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Chade D, et al. Impact of statin use on oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol. 2013;190:487–92.

    Article  PubMed  Google Scholar 

  19. Defronzo RA, Mehta RJ, Schnure JJ. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus. Hosp Pract. 1995;2013(41):132–47.

    Google Scholar 

  20. Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35:1835–44.

    Article  PubMed  Google Scholar 

  21. Xu X, Wu J, Mao Y, Zhu Y, Hu Z, Xu X, et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS One. 2013;8:e58079.

    Article  PubMed  Google Scholar 

  22. Schuhmacher-Wolz U, Dieter HH, Klein D, Schneider K. Oral exposure to inorganic arsenic: evaluation of its carcinogenic and non-carcinogenic effects. Crit Rev Toxicol. 2009;39:271–98.

    Article  PubMed  CAS  Google Scholar 

  23. Zaghloul MS. Bladder cancer and schistosomiasis. J Egypt Natl Canc Inst. 2012;24:151–9.

    Article  PubMed  Google Scholar 

  24. Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, et al. Multivitamins in the prevention of cancer in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2012;308:1871–80.

    Article  PubMed  CAS  Google Scholar 

  25. Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, Schvartz M, et al. Multivitamins in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2012;308:1751–60.

    Article  PubMed  CAS  Google Scholar 

  26. Neuhouser ML, Wasserthell-Smoller S, Thomson C, Aragaki A, Anderson GL, Manson JE, et al. Multivitamin use and risk of cancer and cardiovascular disease in the Women’s Health Initiative cohorts. Arch Intern Med. 2009;169:294–304.

    Article  PubMed  Google Scholar 

  27. Cole BF, Baron JA, Sandler RS, Polyp Prevention Study Group, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA. 2007;297:2351–9.

    Article  PubMed  CAS  Google Scholar 

  28. Figueriredo JC, Grau MV, Haile RW, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst. 2009;101:432–5.

    Article  Google Scholar 

  29. Collin SM, Metcalfe C, Refsum H, Lewis SJ, Zuccolo L, Smith GD, et al. Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case–control study, systematic review, and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2010;19:1632–42.

    Article  PubMed  CAS  Google Scholar 

  30. Bailey RL, Mills JL, Yetley EA, Gahche JJ, Pfeiffer CM, Dwyer JT, et al. Unmetabolized serum folic acid and its relation to folic acid intake from diet and supplements in a nationally representative sample of adults aged > or =60 y in the United States. Am J Clin Nutr. 2010;92:383–9.

    Article  PubMed  CAS  Google Scholar 

  31. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009;301:39–51.

    Article  PubMed  CAS  Google Scholar 

  32. Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs Jr GF, Nutritional Prevention of Cancer Study Group, et al. Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst. 2003;95:1477–81.

    Article  PubMed  CAS  Google Scholar 

  33. Stranges S, Marshall JR, Natarajan R, Donahue RP, Trevisan M, Combs GF, et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med. 2007;147:217–23.

    Article  PubMed  Google Scholar 

  34. Lawson KA, Wright ME, Subar A, Mouw T, Hollenbeck A, Schatzkin A, et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. J Natl Cancer Inst. 2007;99:754–64.

    Article  PubMed  CAS  Google Scholar 

  35. Miller 3rd ER, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37–46.

    Article  PubMed  CAS  Google Scholar 

  36. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, B-vitamin Treatment Trialists’ Collaboration, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality. Meta-analysis of 8 randomized trials involving 37,485 individuals. Arch Intern Med. 2010;170:1622–31.

    Article  PubMed  CAS  Google Scholar 

  37. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. JAMA. 2008;300:2123–33.

    Article  PubMed  CAS  Google Scholar 

  38. Lamm DL, Riggs DR, Shriver JS, van Gilder PF, Rach JF, De Haven JI. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol. 1994;151: 21–6.

    PubMed  CAS  Google Scholar 

  39. Nepple KG, Lightfoot AJ, Rosevear HM, O’Donnell MA, Lamm DL, Bladder Cancer Genitourinary Oncology Study Group. Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. J Urol. 2010;184:1915–9.

    Article  PubMed  Google Scholar 

  40. Moyad MA. Dr. Moyad’s no bogus science health advice. Ann Arbor, MI: Ann Arbor Media Group; 2010.

    Google Scholar 

  41. Morris MC, Tangney CC. A potential design flaw of randomized trials of vitamin supplements. JAMA. 2011;305:1348–9.

    Article  PubMed  CAS  Google Scholar 

  42. Tighe P, Ward M, McNulty H, Finnegan O, Dunne A, Strain J, et al. A dose-finding trial of the effect of long-term folic acid intervention: implications for food fortification policy. Am J Clin Nutr. 2011;93: 11–8.

    Article  PubMed  CAS  Google Scholar 

  43. Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, et al. The SU.VI.MAX study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004;164:2335–42.

    Article  PubMed  CAS  Google Scholar 

  44. Goossens ME, Buntinx F, Joniau S, Ackaert K, Ameye F, Billet I, et al. Designing the selenium and bladder cancer trial (SELEBLAT), a phase III randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium. BMC Urol. 2012;12:8.

    Article  PubMed  CAS  Google Scholar 

  45. Moyad MA. Selenium and vitamin E supplements for prostate cancer: evidence or embellishment? Urology. 2002;59(4 Suppl 1):9–19.

    Article  PubMed  Google Scholar 

  46. Giovannucci E, Chan AT. Role of vitamin and mineral supplementation and aspirin use in cancer survivors. J Clin Oncol. 2010;28:4081–5.

    Article  PubMed  CAS  Google Scholar 

  47. Aso Y, Akazan H, BLP Study Group. Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. Urol Int. 1992;49:125–9.

    Article  PubMed  CAS  Google Scholar 

  48. Aso Y, Akaza H, Kotake T, Tsukamoto T, Imai K, Naito S. Prevention effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur Urol. 1995;27: 104–9.

    PubMed  CAS  Google Scholar 

  49. Naito S, Koga H, Yamaguchi A, Fujimoto N, Hasui Y, Kuramoto H, Kyushu University Urological Oncology Group. Prevention of recurrence with epirubicin and Lactobacillus casei after transurethral resection of bladder cancer. J Urol. 2008;179:485–90.

    Article  PubMed  CAS  Google Scholar 

  50. Dong H, Rowland I, Thomas LV, Yaqoob P. Immunomodulatory effects of a probiotc drink containing Lactobacillus casei Shirota in healthy older volunteers. Eur J Nutr. 2013; [Epub ahead of print].

    Google Scholar 

  51. Dong H, Rowland I, Yaqoob P. Comparative effects of six probiotic strains on immune function in vitro. Br J Nutr. 2012;108:459–70.

    Article  PubMed  CAS  Google Scholar 

  52. Dong H, Rowland I, Tuohy KM, Thomas LV, Yaqoob P. Selective effects of Lactobacillus casei Shirota on T cell activation, natural killer cell activity and cytokine production. Clin Exp Immunol. 2010;161:378–88.

    PubMed  CAS  Google Scholar 

  53. Ohashi Y, Nakai S, Tsukamoto T, Masumori N, Akaza H, Miyanaga N, et al. Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. Urol Int. 2002;68:273–80.

    Article  PubMed  CAS  Google Scholar 

  54. Larsson SC, Andersson SO, Johansson JE, Wolk A. Cultured milk, yogurt, and dairy intake in relation to bladder cancer risk in a prospective study of Swedish women and men. Am J Clin Nutr. 2008;88:1083–7.

    PubMed  CAS  Google Scholar 

  55. Keszei AP, Schouten LJ, Goldbohm RA, van den Brandt PA. Dairy intake and the risk of bladder cancer in the Netherlands Cohort Study on Diet and Cancer. Am J Epidemiol. 2010;171:436–46.

    Article  PubMed  Google Scholar 

  56. Li S, Liu Y, Peng Q, Xie L, Wang J, Qin X. Chewing gum reduces postoperative ileus following abdominal surgery: a meta-analysis of 17 randomized controlled trials. J Gastroenterol Hepatol. 2013;28:1122–32.

    Article  PubMed  Google Scholar 

  57. Choi H, Kang SH, Yoon DK, Kang SG, Ko HY, du Moon G, et al. Chewing gum has a stimulatory effect on bowel motility in patients after open or robotic radical cystectomy for bladder cancer: a prospective randomized comparative study. Urology. 2011;77: 884–90.

    Article  PubMed  Google Scholar 

  58. Kouba EJ, Wallen EM, Pruthi RS. Gum chewing stimulates bowel motility in patients undergoing radical cystectomy with urinary diversion. Urology. 2007;70:1053–6.

    Article  PubMed  Google Scholar 

  59. Pruthi RS, Nielsen M, Smith A, Nix J, Schultz H, Wallen EM. Fast track program in patients undergoing radical cystectomy: results in 362 consecutive patients. J Am Coll Surg. 2010;210:93–9.

    Article  PubMed  Google Scholar 

  60. Krieger JN, Nyberg Jr L, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282:236–7.

    Article  PubMed  CAS  Google Scholar 

  61. Shoskes DA, Nickel JC, Kattan MW. Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology. 2010;75:1249–53.

    Article  PubMed  Google Scholar 

  62. Giubilei G, Mondaini N, Minervini A, Saieva C, Lapini A, Serni S, Bartoletti R, Carini M. Physical activity of men with chronic prostatitis/chronic pelvic pain syndrome not satisfied with conventional treatments-could it represent a valid option? The physical activity and male pelvic pain trial: a double-blind, randomized study. J Urol. 2007;177:159–65.

    Article  PubMed  Google Scholar 

  63. Pool JL. Role of sympathetic nervous system in hypertension and benign prostatic hyperplasia. Br J Clin Pract Suppl. 1994;74:13–7.

    PubMed  CAS  Google Scholar 

  64. McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2005;174(4 Pt 1):1327–433.

    Article  PubMed  Google Scholar 

  65. Esch T, Stefano GB. The neurobiology of stress management. Neuro Endocrinol Lett. 2010;31:19–39.

    PubMed  Google Scholar 

  66. Murtezani A, Hundozi H, Orovcanec N, Sllamniku S, Osmani T. A comparison of high intensity aerobic exercise and passive modalities for the treatment of workers with chronic low back pain: a randomized, controlled trial. Eur J Phys Rehabil Med. 2011;47: 359–66.

    PubMed  CAS  Google Scholar 

  67. Cohen JM, Fagin AP, Hariton E, Niska JR, Pierce MW, Kuriyama A, et al. Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review and meta-analysis. PLoS One. 2012;7:e41941.

    Article  PubMed  CAS  Google Scholar 

  68. Wagenlehner FM, Bschleipfer T, Pilatz A, Weidner W. Pollen extract for chronic prostatitis-chronic pelvic pain syndrome. Urol Clin N Am. 2011;38:285–92.

    Article  Google Scholar 

  69. Wagenlehner FME, Schneider H, Ludwig M, Schnitker J, Brahler E, Weidner W. A pollen extract (cernilton) in patients with inflammatory chronic-prostatitis-chronic pelvic pain syndrome: a multicentre, randomized, prospective, double-blind, placebo-controlled trial. Eur Urol. 2009;56:544–51.

    Article  PubMed  Google Scholar 

  70. MacDonald R, Ishani A, Rutks I, Wilt TJ. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int. 2000;85:836–41.

    Article  PubMed  CAS  Google Scholar 

  71. Weng Z, Zhang B, Asadi S, Sismanopoulos N, Butcher A, Fu X, et al. Quercetin is more effective than cromolyn in blocking human mast cell cytokine release and inhibits contact dermatitis and photosensitivity in human. PLoS One. 2012;7:e33805.

    Article  PubMed  CAS  Google Scholar 

  72. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 1999;54:960–3.

    Article  PubMed  CAS  Google Scholar 

  73. Theoharides TC, O’Leary M. Painful bladder syndrome/interstitial cystitis: current concepts and role of nutraceuticals. Sem Prev Altern Med. 2006;14:2–6.

    Google Scholar 

  74. Hill JR, Isom-Batz G, Panagopoulos G, Zakariasen K, Kavaler E. Patient perceived outcomes of treatments used for interstitial cystitis. Urology. 2008;71:62–6.

    Article  PubMed  Google Scholar 

  75. Bologna RA, Gomelsky A, Lukban JC, Tu LM, Holzberg AS, Whitmore KE. The efficacy of calcium glycerophosphate in the prevention of food-related flares in interstitial cystitis. Urology. 2001;57(6 Suppl 1):119–20.

    Article  PubMed  CAS  Google Scholar 

  76. Bassaly R, Downes K, Hart S. Dietary consumption triggers in interstitial cystitis pain syndrome patients. Female Pelvic Med Reconstr Surg. 2011;17:36–9.

    Article  PubMed  Google Scholar 

  77. Friedlander JI, Shorter B, Moldwin RM. Diet and its role in interstitial cystitis/bladder pain syndrome (IC/BPS) and comorbid conditions. BJU Int. 2012; 109:1584–91.

    Article  PubMed  Google Scholar 

  78. Nguan C, Franciosi LG, Butterfield NN, Macleod BA, Jens M, Fenster HN. A prospective, double-blind, randomized cross-over study evaluating changes in urinary pH for relieving symptoms of interstitial cystitis. BJU Int. 2005;95:91–4.

    Article  PubMed  Google Scholar 

  79. Thilagarajah R, Wltherow RO, Walker MM. Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled trial. BJU Int. 2001;87:207–12.

    Article  PubMed  CAS  Google Scholar 

  80. O’Hare 3rd PG, Hoffman AR, Allen P, Gordon B, Salin L, Whitmore K. Interstitial cystitis patients’ use and rating of complementary and alternative medicine therapies. Int Urogynecol J. 2013;24:977–82.

    Article  PubMed  Google Scholar 

  81. Theoharides TC, Sant GR. A pilot open label study of Cystoprotek in interstitial cystitis. Int J Immunopathol Pharmacol. 2005;18:183–8.

    PubMed  CAS  Google Scholar 

  82. Theoharides TC, Kempuraj D, Vakall S, Sant GR. Treatment of refractory interstitial cystitis/painful bladder syndrome with CystoProtek-an oral multi-agent natural supplement. Can J Urol. 2008;15:4410–4.

    PubMed  CAS  Google Scholar 

  83. Smith SD, Wheeler MA, Foster Jr HE, Weiss RM. Improvement in interstitial cystitis symptom scores during treatment with oral L-arginine. J Urol. 1997;158(3 Pt 1):703–8.

    PubMed  CAS  Google Scholar 

  84. Korting GE, Smith SD, Wheeler MA, Weiss RM, Foster Jr HE. A randomized double-blind trial of oral L-arginine for treatment of interstitial cystitis. J Urol. 1999;161:558–65.

    Article  PubMed  CAS  Google Scholar 

  85. Cartledge JJ, Davies AM, Eardley I. A randomized double-blind placebo-controlled crossover trial of the efficacy of L-arginine in the treatment of interstitial cystitis. BJU Int. 2000;85:421–6.

    Article  PubMed  CAS  Google Scholar 

  86. Ehren I, Lundberg JO, Adolfsson J, Wiklund NP. Effects of L-arginine treatment on symptoms and bladder nitric oxide levels in patients with interstitial cystitis. Urology. 1998;52:1026–9.

    Article  PubMed  CAS  Google Scholar 

  87. Katske F, Shoskes DA, Sender M, Poliakin R, Gagliano K, Rajfer J. Treatment of interstitial cystitis with a quercetin supplement. Tech Urol. 2001;7:44–6.

    PubMed  CAS  Google Scholar 

  88. Fageril J, Fraser MO, de Groat WC, Chancellor MB, Flood HD, Smith D, et al. Intravesical capsaicin for the treatment of interstitial cystitis: a pilot study. Can J Urol. 1999;6:737–44.

    Google Scholar 

  89. French LM, Bhambore N. Interstitial cystitis/painful bladder syndrome. Am Fam Physician. 2011;83: 1175–81.

    PubMed  Google Scholar 

  90. Lipworth L, Tarone RE, McLaughlin JK. Renal cell cancer among African Americans: an epidemiologic review. BMC Cancer. 2011;11:133.

    Article  PubMed  Google Scholar 

  91. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7:245–57.

    Article  PubMed  Google Scholar 

  92. Moyad MA. Obesity, interrelated mechanisms, and exposures and kidney cancer. Semin Urol Oncol. 2001;19:270–9.

    PubMed  CAS  Google Scholar 

  93. Khurana V, Caldito G, Ankem M. Statins might reduce risk of renal cell carcinoma in humans: case–control study of 500,000 veterans. Urology. 2008;71: 118–22.

    Article  PubMed  Google Scholar 

  94. Behrens G, Leitzmann MF. The association between physical activity and renal cancer: systematic review and meta-analysis. Br J Cancer. 2013;108:798–811.

    Article  PubMed  CAS  Google Scholar 

  95. Willett WC. Fruits, vegetables, and cancer prevention: turmoil in the produce section. J Natl Cancer Inst. 2010;102:1–2.

    Article  Google Scholar 

  96. Macleod LC, Hotaling JM, Wright JL, Davenport MT, Gore JL, Harper J, et al. Risk factors for renal cell carcinoma in the Vitamin and Lifestyle (VITAL) Study. J Urol. 2013; [epub ahead of print].

    Google Scholar 

  97. Lai GY, Park Y, Hartge P, Hollenbeck AR, Freedman ND. The association between self-reported diabetes and cancer incidence in the NIH-AARP Diet and Health Study. J Clin Endocrinol Metab. 2013;98:E497–502.

    Article  PubMed  CAS  Google Scholar 

  98. Shu X, Lin J, Wood CG, Tannir NM, Wu X. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk. J Natl Cancer Inst. 2013;105:424–32.

    Article  PubMed  CAS  Google Scholar 

  99. Beebe-Dimmer JL, Colt JS, Ruterbusch JJ, Keele GR, Purdue MP, Wacholder S, et al. Body mass index and renal cell cancer: the influence of race and sex. Epidemiology. 2012;23:821–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Michigan Medical Center, Ann Arbor, MI, USA

    Mark A. Moyad M.D., M.P.H.

Authors
  1. Mark A. Moyad M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Moyad, M.A. (2014). Review of Lifestyle and CAM for Miscellaneous Urologic Topics (Bladder Cancer, CP/CPPS, IC/PBS, Kidney Cancer): Part One. In: Complementary & Alternative Medicine for Prostate and Urologic Health. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8492-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8492-9_9

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8491-2

  • Online ISBN: 978-1-4614-8492-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation